RIGL Rigel Pharmaceuticals

$RIGL Also, interesting that short interest dropped below 3M shares to 2,855,433 shares as of 9/30. So we're down about 1.3M shares short since 4/15 and down 350k shares short since 9/15.

$RIGL the question still remains: Who’s gonna sell these 3+ million shares in order for them to get out? Are they counting on negative sales from Vepp? 😂.. The last forcats was revised higher and still didn’t have any Vepp sales calculated in. These shorts are barely hanging on and are apparently not willing to just cut losses now. Crazy to me.

$RIGL I think we're looking good coming up on Nov earnings. Our Q3 last year was a beat and it's numbers are over what our expected earning are for this quarter... which obviously didn't account for veppanu numbers we'll have this go-around. We've held share price exceptionally well this quarter thus far...so I think we beat in Nov and see a breakout finally above $50...BUT that's just my .02 guestimate. ;) GLTA!

$RIGL Each Veppanu customer taking the medication for 1 year adds a penny to annual earnings. $350K price per year minus expenses and taxes = $185K/year earnings with 18.5 million shares is .01/share earnings. 10 patients equals 10 cents in earnings 100 patients = $1.00 a share in earnings 500 patients = $5.00 EPS 1000 patients = $10 EPS

$RIGL I’ve done a lot of research on this like most on this board and I cannot see why this has such high short interest. Of all of the other bios that make zero revenue or profit and all the high flying tech stocks with negative PE or extremely high; why short this one? They have added drugs and the cash flow gets better and better with the debt lower and lower. I mean why do that? I simply do not see the reason to be around 20 percent short on this.

$RIGL Rigel’s outstanding shares on Schwab says 18.68 million so rounding up to 19 million getting us to a $1 billion market cap should be -$52+. My next targets will then be $1.25 and $1.5 billion by year end. Didnt check what fully diluted shares are with any options, warrants etc if any knows? Enough of this price manipulation BS from last week. It’s long overdue IMO. So let’s make some more noise if you agree. DYOR and MYODs. GLTA!

$RIGL Fear not! Unless you are short! The biggest M&A month of the year in Bio kicks off in 2 days. LFG

$RIGL Just a bit more teeter-tottering in the $46-$49 area while shorts are stuck & retail is seemingly unaware of this gem (typical of retail to only board the ship after the fact)...& then, come the November EC, the SP should surpass the 52-week high of $52.24, &, after that, we'll be off to the races. Granted, the November EC will only show a partial quarter of sales, given it's their first quarter with VEPPANU available, but I think we'll at least see that the baby's kicking. Even if the ramp-up in VEPPANU isn't as fast as we might like (this Q), we're still profitable, growing, & VEPPANU will grow in the coming quarters anyway. This is a great investment. Recall my post from May (https://stocktwits.com/biid/message/653461504), where I state that the first $150M out of the 1B+ market opportunity represented by VEPPANU will be relatively easy for the company to attain. Factor in that they're leveraging existing infrastructure to make that happen, & I feel really confident about the company's chances.

$RIGL Dino’s talk was full of great content. His words not mine-we believe Vep has a well over a billion dollar market opportunity. He laid out how the salesforce is reaching the care providers. Was strong on guidance and said that it doesn’t consider Vep which they believe is a considerable opportunity. Added more! Volume is terrible today, but this will rocket if Vep is anything like they are projecting.

$RIGL Some further background. „While a phase 1b study (of R289) might seem like a long way away from bringing the drug to market, the company notes it will engage the regulator about a potential registrational study following phase 1b results ( to happen this q). RIGL's CMO also spoke about the potential to expand R289 into other potential indications with Q2'26 earnings, so R289 could develop into a much more interesting part of RIGL's pipeline in the next six months.” (If the trial is successful and the drug has strong differentiation; therein lies a potential multi-billion $ mkt. An announced trial start of a phase 1b could cause a nice surge in our price!)

$RIGL I noticed a fun thing when I was reviewing some research on RIGL: The Q2/26 comparison to Q2/25....well, golly gee whiz it doesn't look so good. Duh, that's because Q2/25 had that $40M of non-cash revenue. Brilliant research and analysis. The Q3/26 comparison to Q3/25 should make that little issue go away. Then, RIGL will show up big-time on some dumb screens.

$RIGL great presentation by Dean, he is super bullish on the Vep launch. Nice to hear such extreme confidence, sounds like we can expect great things from Q3 earnings. No update on early sales numbers, but I’m okay with that - just means we’ll get a bigger blowout when they report earnings.

$RIGL got me some more. 20 days until cc. Also not sure if they will drop any news at ESMO end of Oct. I’m thinking not, but 20 days is no time for a growing cash position and upward revisions.

$RIGL Anybody ever wonder if Pfizer did something to Rigel on Fost and Covid. Vep was under table compensation. I love conspiracy theories. If it truly is a billion a year in 2030s, that’s gonna be some serious long term coin.

$RIGL Last couple days have clearly been an accumulation of retail shares and some short covering. I think we're getting closer to something big strategically that tutes are prepping for.

$RIGL My sense here is it will continue to hover around the 40’s, maybe dip into the high 30’s again, and then start to move up again in October prior to earnings in early November. I don’t think a squeeze will happen without some catalyst from good news announced, most likely earnings and/or vep sales exceeding street expectations…so probably won’t see real movement until November. I also think they’ve subtly signaled confidence in the R289 program, and there’s potentially another rerating on the horizon if that program moves forward. We should know around the same time or a little after earnings. Knowing whether the ASH presentation is in-person or just a poster should be an early sign. Very bullish, despite short games being played in the meantime.

$RIGL Rigel confirmed today that the VEPPANU launch is on track. The drug became commercially available in August 2026, and patients started receiving it almost immediately. Rigel believes VEPPANU could eventually become its largest product, even bigger than TAVALISSE. The company sees a potential market opportunity of more than $1.X billion. Rigel estimates around 20,000 eligible patients in the relevant second- and third-line treatment setting. The company has built a dedicated commercial team to support the launch. Rigel has now achieved eight consecutive quarters of profitability. Its 2026 revenue guidance remains $285–295 million, excluding VEPPANU sales. R289 is another major upcoming catalyst, with preliminary data expected by the end of 2026. Overall, today’s update is bullish, although the first meaningful VEPPANU sales numbers could be the much bigger stock-price catalyst.

$RIGL Lol whoever did that successfully pranked the hell out of me. I jumped out of bed and sprinted to my office. My wife was positive the house was on fire or someone died. 0.3 shares traded... hilarious... now please dont do that again so I dont have an early heart attack.

$RIGL I'm getting worried about this market so I put in a 500 share sell order at 46 earlier today. They brought it back up and took those shares, then dropped it again. Might be meaningless, but it looks like they're trying to get retail to sell as they accumulate. NFA

$RIGL I would think by this upcoming earnings report or the next that this shit has to stop...... Big red days do not make any sense!